by Neurological biomarkers play a crucial role in the diagnosis, treatment monitoring and prognosis of neurological disorders like Alzheimer’s disease, Parkinson’s disease, epilepsy and multiple sclerosis. These biomarkers aid in early detection and effective management of neurological conditions. They help assess the biological state of the nervous system and detect molecular, genetic and imaging changes indicative of neurological diseases.
The global Neurological Biomarkers Market is estimated to be valued at US$ 11813.64 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing focus on diagnosis of neurological disorders: Advances in neurological biomarker research have enabled earlier diagnosis of diseases like Alzheimer’s and Parkinson’s. Biomarkers help identify these conditions in their pre-symptomatic stage allowing for timely intervention. Biomarkers enable accurate diagnosis especially for patients presenting atypical symptoms and aid differential diagnosis between neurological diseases. This is resulting in growing focus of researchers and industry players on discovering novel biomarkers for improving diagnosis. For instance, biomarkers like amyloid-β 42 peptides, total tau and phosphorylated tau proteins allow accurate diagnosis of Alzheimer’s years before the onset of clinical symptoms. The increasing emphasis on early diagnosis of neurological disease through biomarkers is a major trend driving the market growth.
SWOT Analysis
Strength: Neurological biomarkers have strong diagnostic potential to detect conditions such as Alzheimer’s, Parkinson’s disease, traumatic brain injury (TBI), and other neurological disorders. They provide insights into disease etiology, progression, and therapeutic responses.
Weakness: Accuracy and reliability of neurological biomarkers still needs to be improved. Developing widely accepted standard panels requires extensive validation studies and clinical trials. Extensive clinical validation is required before widespread clinical implementation.
Opportunity: Advancing technologies such as proteomics, genomics, transcriptomics, metabolomics, and imaging are enhancing the discovery and validation of novel neurological biomarkers. This is expanding their applications across healthcare systems worldwide.
Threats: Stringent regulatory pathways for approving neurological biomarkers as recognized diagnostic tools. Limited reimbursement policies create barriers to their routine clinical adoption and commercialization. Intense competition among key players to commercialize proprietary biomarker panels.
Key Takeaways
The Global Neurological Biomarkers Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Neurological Biomarkers Market is estimated to be valued at US$ 11813.64 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the global market currently due to high disease prevalence, priority research funding, and extensive clinical adoption of biomarkers. Europe trails behind in market share terms. Asia Pacific is witnessing fastest growth with increasing healthcare investments and expanding clinical research activities in major Asian countries.
Key players: Key players operating in the neurological biomarkers market include Knauf Gips KG, LafargeHolcim, National Gypsum Company, Saint-Gobain Group, Yoshino Gypsum Co., Ltd., ACG Materials, Anhydritec, BNZ Materials Inc., American Gypsum, and Gyptec Iberica. These players are focused on developing novel biomarker discovery platforms integrated with multi-omics technologies. They are also engaged in extensive clinical research collaborations to validate biomarker performance across diverse neurological disorders.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
